118 related articles for article (PubMed ID: 15469477)
1. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs).
Goto A; Niki T; Terado Y; Fukushima J; Fukayama M
Histopathology; 2004 Oct; 45(4):384-92. PubMed ID: 15469477
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of CK19 and CD99 in pancreatic endocrine tumors.
Ali A; Serra S; Asa SL; Chetty R
Am J Surg Pathol; 2006 Dec; 30(12):1588-94. PubMed ID: 17122516
[TBL] [Abstract][Full Text] [Related]
3. CEACAM1 expression in pancreatic endocrine tumors.
Serra S; Asa SL; Bamberger AM; Wagener C; Chetty R
Appl Immunohistochem Mol Morphol; 2009 Jul; 17(4):286-93. PubMed ID: 19349857
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of solid pseudopapillary tumors of the pancreas: the expression pattern of CD99 is highly unique.
Li L; Li J; Hao C; Zhang C; Mu K; Wang Y; Zhang T
Cancer Lett; 2011 Nov; 310(1):9-14. PubMed ID: 21775056
[TBL] [Abstract][Full Text] [Related]
5. Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas.
Guo Y; Yuan F; Deng H; Wang HF; Jin XL; Xiao JC
Am J Surg Pathol; 2011 Jun; 35(6):799-806. PubMed ID: 21566515
[TBL] [Abstract][Full Text] [Related]
6. Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors.
Pelosi G; Leon ME; Veronesi G; Spaggiari L; Pasini F; Viale G
J Thorac Oncol; 2006 Jun; 1(5):468-77. PubMed ID: 17409901
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers.
Llombart B; Monteagudo C; López-Guerrero JA; Carda C; Jorda E; Sanmartín O; Almenar S; Molina I; Martín JM; Llombart-Bosch A
Histopathology; 2005 Jun; 46(6):622-34. PubMed ID: 15910593
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the expression and significance of Claudin-5 and CD99 in solid-pseudopapillary neoplasms and neuroendocrine tumors of pancreas].
Zheng HY; Shi YH; Zhang LF; Chen YZ
Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):372-5. PubMed ID: 24060069
[TBL] [Abstract][Full Text] [Related]
9. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
10. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
[TBL] [Abstract][Full Text] [Related]
11. [The study of the expression and the prognostic value of Survivin and Ki67 in pancreatic endocrine tumors].
Liu WW; Zheng Y; Xia ZL; Zhang SQ; Bao F; Lin ZM; Ji XH; Ying LL; Zhao LL; Xu MF; Cai Guo-Ping ; Chen GR
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2015 Jan; 31(1):72-5. PubMed ID: 26016245
[TBL] [Abstract][Full Text] [Related]
12. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours.
Pelosi G; Fraggetta F; Sonzogni A; Fazio N; Cavallon A; Viale G
Virchows Arch; 2000 Sep; 437(3):270-4. PubMed ID: 11037347
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactivity of CD99 in invasive malignant melanoma.
Wilkerson AE; Glasgow MA; Hiatt KM
J Cutan Pathol; 2006 Oct; 33(10):663-6. PubMed ID: 17026517
[TBL] [Abstract][Full Text] [Related]
14. CK19 and CD99 immunoexpression profile in goblet cell (mucin-producing neuroendocrine tumors) and classical carcinoids of the vermiform appendix.
Alsaad KO; Serra S; Perren A; Hsieh E; Chetty R
Int J Surg Pathol; 2007 Jul; 15(3):252-7. PubMed ID: 17652531
[TBL] [Abstract][Full Text] [Related]
15. Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases.
Buxton D; Bacchi CE; Gualco G; Weiss LM; Zuppan CW; Rowsell EH; Huang Q; Wang J
Am J Clin Pathol; 2009 Apr; 131(4):574-9. PubMed ID: 19289593
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours.
La Rosa S; Rigoli E; Uccella S; Novario R; Capella C
Histopathology; 2007 Apr; 50(5):597-606. PubMed ID: 17394496
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of intraductal papillary neoplasia of the biliary tract and pancreas.
Kloek JJ; van der Gaag NA; Erdogan D; Rauws EA; Busch OR; Gouma DJ; ten Kate FJ; van Gulik TM
Hum Pathol; 2011 Jun; 42(6):824-32. PubMed ID: 21292296
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors.
Lindberg D; Hessman O; Akerström G; Westin G
Neuroendocrinology; 2007; 86(2):112-8. PubMed ID: 17664862
[TBL] [Abstract][Full Text] [Related]
19. CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.
Czapiewski P; Wełnicka-Jaśkiewicz M; Seroczyńska B; Skokowski J; Sejda A; Szade J; Wiewiora C; Biernat W; Żaczek A
Pol J Pathol; 2015 Sep; 66(3):269-75. PubMed ID: 26619106
[TBL] [Abstract][Full Text] [Related]
20. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.
Schmitt AM; Anlauf M; Rousson V; Schmid S; Kofler A; Riniker F; Bauersfeld J; Barghorn A; Probst-Hensch NM; Moch H; Heitz PU; Kloeppel G; Komminoth P; Perren A
Am J Surg Pathol; 2007 Nov; 31(11):1677-82. PubMed ID: 18059224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
